Has Bruce Bode, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,259,897 in general payments to Bruce Bode, MD across 4,721 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bruce Bode, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bruce Bode, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bruce Bode, MD

Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1841297751

Payments from drug & device makers

$18,259,897in general payments, 2019–2025

Across 4,721 payments — averaging $3867.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$4.9M
Abbott$3.1M
Eli Lilly$2.4M
Senseonics, Incorporated$2.3M
Dexcom, Inc.$2.3M
Insulet Corporation$1.3M
plus $2M from 54 others

$163,155in research payments, 2019–2025

Across 9 payments — averaging $18,128 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$94K
Sanofi US Services Inc.$69K
Sanofi-aventis U.S. LLC$309

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	562	$4,903,862
Abbott	581	$3,088,936
Eli Lilly	94	$2,369,343
Senseonics, Incorporated	124	$2,344,021
Dexcom, Inc.	90	$2,251,486
Insulet Corporation	160	$1,328,903
Lilly USA, LLC	422	$327,084
Novo Nordisk	455	$320,165
Sanofi-aventis U.S. LLC	273	$239,811
Sanofi US Services Inc.	142	$205,824
Novo Nordisk AS	598	$198,971
Mannkind Corporation	233	$172,426
Sequel Med Tech, LLC	17	$116,505
Xeris Pharmaceuticals, Inc.	153	$89,527
Janssen Research & Development, LLC	11	$52,430
Companion Medical, Inc.	5	$40,489
AstraZeneca(2 entities)	82	$29,277
Boehringer Ingelheim	75	$26,033
Johnson & Johnson	40	$25,800
Bayer	14	$22,621
Dompe Farmaceutici S.p.a.	8	$20,315
Cequr Corporation	9	$15,821
Astrazeneca UK Limited	2	$10,988
Tandem Diabetes Care, Inc.	45	$9,798
Ascensia Diabetes Care US Inc.	14	$9,146
Zealand Pharma US, Inc.	26	$8,891
Pfizer	7	$7,608
Zealand Pharma A/s	1	$3,750
Lexicon Pharmaceuticals, Inc.	3	$3,499
GSK	1	$3,341
BETA Bionics, Inc.	45	$2,197
Amgen(2 entities)	78	$1,363
Intuity Medical Inc	5	$1,319
Vertex	1	$1,170
Corcept Therapeutics	50	$1,040
Bigfoot Biomedical Inc	12	$726
Novartis	31	$624
Amneal Pharmaceuticals LLC	27	$518
AbbVie	24	$433
Amarin Pharma, Inc.	26	$418
IBSA Pharma Inc.	19	$345
Radius Health, Inc.	16	$322
Merck	15	$254
Valeritas, Inc.	6	$241
BD	10	$195
Averitas Pharma Inc.	7	$178
GRT US Holding, Inc.	8	$157
Endo Pharmaceuticals Inc.	8	$140
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	8	$129
Esperion Therapeutics, Inc.	9	$128
Madrigal Pharmaceuticals	4	$127
Clarus Therapeutics Inc.	3	$92
Ipsen Biopharmaceuticals, Inc	4	$90
Recordati_rare_diseases_inc.	5	$87
Kvk-tech, Inc.	7	$80
Embecta Corp.	4	$80
Ascendis Pharma Endocrinology Inc	3	$63
Nalpropion Pharmaceuticals LLC	3	$52
Janssen Scientific Affairs, LLC	1	$47
Amphastar Pharmaceuticals, Inc.	2	$45

How this compares

$18,259,897 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024

$600,896

Medicare patients

850

Services billed

29,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Atlanta

Gulliermo UmpierrezAtlanta$6.6M
David RobertsonAtlanta$1.7M
Thomas ZieglerAtlanta$1M
Lawrence PhillipsAtlanta$919K
Georgia DavisAtlanta$592K
Jonathan OwnbyAtlanta$565K
Thaer IdreesAtlanta$505K
Francisco PasquelAtlanta$376K
Mary RheeAtlanta$87K
Kate WheelerAtlanta$25K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →